Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
SPOTLIGHT: Boehringer beats Bayer drug to market
Boehringer Ingelheim won European approval for its new blood thinner Pradaxa to prevent clotting in patients after orthopedic surgery. The OK lets Pradaxa beat to market its supposed future rival, Bayer's yet-to-be-approved Xarelto (rivaroxaban). Report
Be the first to comment
More stories about European approval
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
